News For SRDX From The Last 14 Days Check below for free stories on SRDX the last two weeks.
There are 8 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 10, 2012
|
| 16:19 EDT |  | SRDX |
|
|
February 6, 2012
|
| 08:16 EDT |  | SRDX |
| | 08:14 EDT | | SRDX |
| theflyonthewall.com: | SurModics may have to restate Q4, FY statements | | Gary Maharaj, President and CEO of SurModics, stated, "In the process of preparing our financial statements for the quarter ended December 31, 2011, management determined the need to reevaluate the application of GAAP related to our accounting treatment associated with the fourth quarter 2011 asset impairment charge and the subsequent sale of substantially all the assets of the Pharmaceuticals business. As a result, the Company may need to restate its financial statements for the fourth quarter and fiscal year ended September 30, 2011. While it is unfortunate that this reevaluation is causing a delay in the release of our financial results and earnings call, we stress the fact that any potential adjustments would be non-cash in nature related to the Pharmaceuticals business, and will not affect our results from continuing operations in the first quarter of 2012." :theflyonthewall.com |
| | 08:12 EDT | | SRDX |
| theflyonthewall.com: | SurModics reports preliminary Q1 adjusted EPS 11c vs. consensus 11c | | Sees Q1 revenue from continuing operations $11.9M vs. consensus $12.63M. Results for the first quarter were impacted by a $2.0M decline in royalty revenue associated with Cypher and Cypher Select Plus drug eluting stents. :theflyonthewall.com |
|
|
February 3, 2012
|
| 14:02 EDT |  | SRDX |
| | 05:18 EDT | | SRDX |
| theflyonthewall.com: | SurModics backs FY12 EPS 45c-53c vs. consensus 46c | | Backs FY12 revenue $47M-$51M vs. consensus $50.26M :theflyonthewall.com |
| | 05:17 EDT | | SRDX |
| | 05:14 EDT | | SRDX |
|
|
|
Subscribe for More Information